newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

  • Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy Designation (BTD) from China's NMPA for combination therapy with acalabrutinib.
  • The designation applies to treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • BTD status provides priority communication, development guidance, & potential pathways to Priority Review & conditional approval in China.
  • CLL/SLL affects over 100,000 patients annually globally, with rising incidence & more aggressive presentations in China.
  • Current first-line treatments face limitations regarding efficacy in high-risk patients, insufficient response depth, & the need for continuous dosing.
  • Lisaftoclax was previously approved in China for patients with CLL/SLL who had received prior systemic therapy including BTK inhibitors.
  • It is the first China-developed Bcl-2 inhibitor approved in China & the second globally.
  • The GLORA-2 Phase III trial is evaluating the lisaftoclax-acalabrutinib combination as a first-line treatment for CLL/SLL.
  • The combination remains investigational in the US & has not received approval in any market to date.
  • Ascentage Pharma is conducting four global registrational Phase III trials for lisaftoclax across various hematologic malignancies.